广州医药集团有限公司

Guangzhou Pharmaceutical Holdings Limited is a state-owned enterprise founded in 1996 and headquartered in Guangzhou, Guangdong. It employs 38,500 people and controls Baiyunshan, listed as 600332.SS and 0874.HK. Ownership is split between Guangzhou SASAC at 90% and the Guangdong Provincial Department of Finance at 10%. At the stated 7.12 CNY/USD rate, 2025 revenue was US$4.00 billion and net income was US$71.6 million.

Industry Position

The company is classified in Biopharmaceutical and owns six named brands: Wanglaoji, Baiyunshan, Chenliji, Pangaoshou, Jingxiutang, and Zhongyi. State ownership and control of Baiyunshan link it to municipal oversight and a listed capital-market vehicle. Baiyunshan trades in Shanghai and Hong Kong, giving the group a public-equity presence. No market-share or volume ranking is supplied; position rests on scale, ownership, and financial trajectory.

Revenue rose from US$3.19 billion in 2020 to US$4.00 billion in 2025. Net income moved from US$74.4 million in 2020 to US$98.3 million in 2021, then US$96.9 million, US$95.5 million, US$67.4 million, and US$71.6 million in 2025. Assets increased from US$14.38 billion to US$19.69 billion. The top line and balance sheet expanded, but profit conversion weakened after 2021 and did not recover to that peak.

Competitive Advantages

The brand portfolio is the clearest differentiator. Wanglaoji and Baiyunshan sit with Chenliji, Pangaoshou, Jingxiutang, and Zhongyi, giving the group multiple consumer and pharmaceutical names. Baiyunshan is also the controlled listed subsidiary, so the brand and equity vehicle reinforce each other. The Guangzhou headquarters and 38,500-person workforce indicate substantial operating scale.

State ownership supports long-term capital access and policy alignment. Guangzhou SASAC holds 90%, and the Guangdong Provincial Department of Finance holds 10%, tying the company to municipal and provincial interests. Control of Baiyunshan provides a listed platform for financing and governance, with shares traded as 600332.SS and 0874.HK. These are structural advantages; they do not prove superior margins or market share.

Strategic Expansion

The financial record shows expansion. Revenue increased from 2020 to 2021, dipped slightly in 2022, and then grew through 2025. Assets rose every year, from US$14.38 billion in 2020 to US$19.69 billion in 2025. That asset growth is consistent with an expanding operating base, though the fact pack does not specify capacity, acquisitions, or working capital. Baiyunshan remains the central listed vehicle.

Brand extension is a plausible lever because the group already owns six named brands. Wanglaoji and Baiyunshan are the most prominent in the supplied list, while Chenliji, Pangaoshou, Jingxiutang, and Zhongyi broaden the portfolio. Growth can also run through Baiyunshan's dual listing in Shanghai and Hong Kong. Product volumes, customer concentrations, and segment margins are not disclosed.

Risks & Outlook

The main financial risk is profit quality. Revenue rose from US$3.19 billion in 2020 to US$4.00 billion in 2025, but net income fell from US$98.3 million in 2021 to US$71.6 million in 2025. The 2024 figure of US$67.4 million was the lowest in the series, and the 2025 rebound was modest. Asset growth to US$19.69 billion raises the need to monitor returns.

Ownership concentration is a structural consideration. Guangzhou SASAC holds 90%, and the Guangdong Provincial Department of Finance holds 10%, leaving little minority influence at the parent level. Reliance on Baiyunshan as a listed subsidiary creates governance and disclosure obligations across two markets. Brand concentration around Wanglaoji and Baiyunshan is a strength but also a dependency. Scale and state backing are durable; profit conversion and brand concentration need monitoring.

Guangzhou Pharmaceutical Holdings Limited combines a 1996 founding date, Guangzhou headquarters, 38,500 employees, six listed brands, state ownership, and control of Baiyunshan. Revenue reached US$4.00 billion in 2025, with assets of US$19.69 billion and net income of US$71.6 million. Top-line and balance-sheet expansion have outpaced net income since 2021. On the supplied facts, it merits a VerityRank Score of 77/100.